Psychiatric Medications - Children Medications

Written by NIMH

1. Sarafem (fluoxetine HCl)
2. Serzone (nefazodone HCl)
3. Sinequan (doxepin)
4. Surmontil (trimipramine)
5. Symbyax (olanzapine/fluoxetine)
6. Tofranil (imipramine)
7. Tofranil-PM (imipramine pamoate)
8. Triavil (perphenazine/amitriptyline)
9. Vivactil (protriptyline)
10. Wellbutrin (bupropion HCl)
11. Zoloft (sertraline HCl)
12. Zyban (bupropion HCl)

    advertisement

Publications Guidelines

This publication is in the public domain and may be reproduced or copied without the permission from the Institute (NIMH). NIMH encourages you to reproduce them and use them in your efforts to improve public health. Citation of the National Institute of Mental Health as a source is appreciated. However, using government materials inappropriately can raise legal or ethical concerns, so we ask you to use these guidelines:

• NIMH does not endorse or recommend any commercial products, processes or services, and our publications may not be used for advertising or endorsement purposes.
• NIMH does not provide specific medical advice or treatment recommendations or referrals; our materials may not be used in a manner that has the appearance of such information.
• NIMH requests that non-federal organizations not alter our publications in ways that will jeopardize the integrity and "brand" intact when using the publication.
• Addition of non-federal government logos and website links may not have the appearance of NIMH endorsement of any specific commercial products or services or medical treatments or services.

If you have questions regarding these guidelines and use of NIMH publications please contact the NIMH Information Center at 1-866-615-6464 or email at nimhinfo@nih.gov.

¹Marder SR, Essock SM, Miller AL, et al. Physical Health Monitoring of Patients With Schizophrenia. Am J Psychiatry. August 2004;161(8):1334-1349.

²Newcomer JW. Clinical considerations in selecting and using atypical antipsychotics. CNS Spect. Aug 2005;10(8 Suppl 8):12-20.

REFERENCES

¹Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry, 2000; 62 (suppl 4): 10-14.

²Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. For the Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Archives of General Psychiatry, 2000; 57(5): 481-489.

³Vainionpää LK, Rättyä J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Annals of Neurology, 1999; 45(4): 444-450.

⁴Soames JC. Valproate treatment and the risk of hyperandrogenism and polycystic ovaries. Bipolar Disorder, 2000; 2(1): 37-41.

⁵Thase ME, and Sachs GS. Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biological Psychiatry, 2000; 48(6): 558-572.

⁶Department of Health and Human Services. 1999. Mental Health: A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institute of Mental Health.

⁷Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, and Mintz J. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. American Journal of Psychiatry, 1996; 153(5): 592-606.

⁸Physicians' Desk Reference, 54th edition. Montavale, NJ: Medical Economics Data Production Co. 2000.

This is the 4th edition of Medications. It was revised by Margaret Strock, staff member in the Science Writing Team, Public Information and Communications Branch, National Institute of Mental Health (NIMH). Scientific review was provided by Wayne Fenton, M.D., Henry Haigler, Ph.D., Ellen Leibenluft, M.D., Matthew Rudorfer, M.D., and Benedetto Vitiello, M.D. Editorial assistance was provided by Lisa Alberts and Ruth Dubois.

NIH Publication No. 02-3929

NIMH publications are in the public domain and may be reproduced or copied without the permission from the National Institute of Mental Health (NIMH). NIMH encourages you to reproduce them and use them in your efforts to improve public health. Citation of the National Institute of Mental Health as a source is appreciated. However, using government materials inappropriately can raise legal or ethical concerns, so we ask you to use these guidelines:

• NIMH does not endorse or recommend any commercial products, processes, or services, and publications may not be used for advertising or endorsement purposes.
• NIMH does not provide specific medical advice or treatment recommendations or referrals; these materials may not be used in a manner that has the appearance of such information.
• NIMH requests that non-Federal organizations not alter publications in a way that will jeopardize the integrity and "brand" when using publications.
• Addition of Non-Federal Government logos and website links may not have the appearance of NIMH endorsement of any specific commercial products or services or medical treatments or services.

If you have questions regarding these guidelines and use of NIMH publications, please contact the NIMH Information Center at 1-866-615-6464 or at nimhinfo@nih.gov.

next: Antidepressant Medications for Children and Adolescents: Information for Parents and Caregivers